Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients

使用再生骨粘合剂加速老年患者骨愈合的四肢骨折改进治疗方法的商业化

• 批准号: 10822079
• 负责人: Brian Hess
• 金额: $ 174.67万
• 依托单位: REVBIO, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10822079
• 关键词: Acceleration; Address; Adhesives; Adverse event; Age; Aging; Anesthesia procedures; Animals; Award; Biological; Cadaver; Carpal Tunnel Syndrome; Clinical Investigator; Clinical Research; Clinical Trials; Complex Regional Pain Syndromes; Complication; Defect; Development; Distal; Elderly; Electroplating; Enrollment; Equation; Event; Failure; Fatigue; Filler; Formulation; Fracture; Fracture Fixation; Funding; Goals; Good Clinical Practice; Grant; Guidelines; Human; Incidence; Infection; Injury; Institution; Intervention; Life; Limb structure; Lower Extremity; Market Research; Metals; Methods; Mission; Modeling; Multi-Institutional Clinical Trial; National Institute on Aging; Operative Surgical Procedures; Orthopedics; Oryctolagus cuniculus; Outcome Study; Patients; Performance; Periodicity; Persons; Phase; Population; Process; Quality of life; Radius Fractures; Recurrence; Regional Anatomy; Reporting; Research; Risk; Rupture; Safety; Sampling; Second Look Surgery; Sheep; Site; Small Business Innovation Research Grant; Specific qualifier value; Sterility; Sterilization; Surgeon; Syndrome; System; Techniques; Tendon structure; Testing; Training; Trauma; Upper Extremity; Validation; Work; biomaterial compatibility; bone; bone fracture repair; bone healing; clinical research site; commercialization; cost; design verification; experience; falls; first-in-human; fragility fracture; healing; image guided; implant design; improved; irritation; mortality; novel; patient population; pre-clinical research; preclinical development; preclinical study; prevent; primary endpoint; product development; programs; radiological imaging; regenerative; safety study; sample fixation; standard of care; standing height; usability; validation studies

Project Abstract/Summary In the U.S., about 2.1 million people experience a fragility fracture each year. This number is expected to double or triple by 2040 as the population ages. Injuries in the upper and lower extremities equate to more than 40% of fragility fractures, and experiencing a prior fracture is associated with an 86% increased risk of recurrence. Falls from standing height and other low-energy trauma account for 87% of all orthopedic fractures among the elderly. External fixation, percutaneous pinning, and open reduction internal fixation with locking plates are interventions that are currently being used to treat extremity fractures. Despite advances in surgical technique and implant design, nonunion, malunion, and hardware failure continue to remain a significant cause of revision surgery in the elderly. Complication rates as high as 36% have been reported and involve onset of carpal tunnel syndrome, complex regional pain syndrome, tendon irritation and rupture, and deep infection. To address this problem, RevBio developed Tetranite® (TN), a novel bone adhesive that can fill gaps in bone, fixate bone fragments, and accelerate healing through its osteoconductive effects. TN can be used as an adjunct to traditional hardware fixation to provide immediate load sharing between the metal plate and screw systems, and bone. It provides additional stability by enhancing fracture stabilization to achieve better healing and prevents hardware failure. It can also be injected percutaneously a standalone method of fixation providing an option to surgically treat fractures without the need for open reduction, metal hardware, or anesthesia. Proposed work to treat extremity fractures in the elderly will bridge off existing late-stage development of TN supported by a SBIR Phase II award from the National Institutes of Aging entitled, “Improved Treatment of Distal Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive” (R44 AG060881- 02). This grant enabled formulation optimization and conduction of user validation studies with surgeons (Aim 1) and a pivotal animal study in sheep (Aim 2) to demonstrate safety and efficacy of TN. This project is focused on a specific indication to treat distal radius fractures; however, based on discussions with FDA and surgeons, the impact and value of the material could be expanded to a wider set of indications across all metaphyseal fractures in the upper and lower extremities for this same patient population. Therefore, this grant would provide additional funding to conduct market research and supplemental pre-clinical development costs to expand its use to these additional anatomic regions. This funding would also enable completion of biocompatibility, sterilization, packaging, and shelf-life validations to finish late-stage development, enabling RevBio to file an IDE, and execute a clinical study with TN as an adjunct to hardware. The overarching goal of this program is to build off successful Phase II research and to execute Aim 1 and Aim 2 to lead to product regulatory approval for commercialization. Long term, RevBio’s mission is to commercialize TN in order to provide surgeons with a novel product that will enhance fixation, accelerate healing, and reduce complications associated with extremity fractures in the elderly.

项目摘要/摘要 在美国，每年约有210万人经历脆弱骨折。这一数字预计将翻一番 或到2040年随着人口老龄化而翻两番。上肢和下肢的损伤相当于超过40%的 脆性骨折和既往骨折与复发风险增加86%相关。瀑布 来自站立高度等低能量创伤占老年人骨科骨折总数的87%。 外固定、经皮穿针、切开复位带锁钢板内固定是干预措施。 目前正被用于治疗四肢骨折。尽管外科技术和植入物取得了进步 设计、骨不连、畸形愈合和硬件故障仍然是翻修手术的主要原因。 老年人。据报道，并发症发生率高达36%，包括腕管综合征的发病， 复杂的局部疼痛综合征，肌腱刺激和断裂，以及深部感染。 为了解决这个问题，RevBio开发了Tetranite®(TN)，这是一种新型的骨粘剂，可以填补骨骼的缺口， 固定骨骼碎片，并通过其骨传导作用加速愈合。TN可以用作附加语 相对于传统的硬件固定以在金属板和螺丝系统之间提供即时的载荷分担， 还有骨头。它通过增强骨折稳定性来提供额外的稳定性，以实现更好的愈合和 防止硬件故障。它还可以经皮注射作为一种独立的固定方法，提供 选择手术治疗骨折，而不需要切开复位、金属硬件或麻醉。 拟议的治疗老年人四肢骨折的工作将消除现有的TN晚期发展 由国家老龄研究所颁发的SBIR第二阶段奖支持，该奖项题为“改善对老年人的治疗” 使用一种新型骨粘合剂的图像引导、经皮递送的桡骨骨折“(R44 AG060881- 02)。这笔赠款使优化配方和与外科医生进行用户验证研究成为可能(目标1) 以及一项关键的绵羊动物研究(目标2)，以证明TN的安全性和有效性。这个项目的重点是 治疗桡骨远端骨折的具体适应症；然而，根据与FDA和外科医生的讨论， 这种材料的影响和价值可以扩大到所有干骺端骨折的更广泛的适应症。 在同样的患者群体的上肢和下肢。因此，这笔赠款将提供额外的 提供资金进行市场研究和补充临床前开发成本，以将其用途扩大到这些 附加的解剖区域。这笔资金还将使完成生物相容性、灭菌、 打包和保质期验证以完成后期开发，使RevBio能够提交IDE并执行 TN作为硬件辅助的临床研究。这一计划的首要目标是在成功的基础上 第二阶段研究并执行目标1和目标2，以导致产品监管批准商业化。 从长远来看，RevBio的使命是将TN商业化，以便为外科医生提供一种新产品，这种产品将 加强固定，加速愈合，减少老年人四肢骨折相关并发症。